Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Genfar

Sanofi reception

Sanofi and Amgen poised for cholesterol drug sales

Praluent to be assessed by FDA advisory committee later this week

- PMLiVE

Sanofi rare disease drug a breakthrough, says FDA

Regulator awarded the status to olipudase alfa for metabolic disorder

- PMLiVE

IQWiG unimpressed with Tresiba for children

German cost watchdog says Novo’s insulin may in fact cause more harm in certain patients

- PMLiVE

Sanofi pays $245m for FDA priority review voucher

PRV reduces review time from ten to six months

Sanofi reception

Sanofi licenses cardiovascular therapy in South Korea

Phase III drug comes from Swedish company NeuroVive

Sanofi appoints Suresh Kumar as EVP of external affairs

He previously worked for the Clinton Foundation focused on Sub-Saharan Africa

Sanofi reception

Sanofi says sarilumab filing for arthritis on track

Looks likely to be filed before the end of the year

- PMLiVE

Endo buys Par for $8bn as M&A mania marches on

Acquisitionwill make Endo the fifth largest generics company in the US

- PMLiVE

Heart drug sales continue downward spiral

But revenue has stabilised after a tough three years of patent expiries

Sanofi reception

Poor Lantus sales sees Sanofi’s diabetes unit fall

French firm hit by insulin pricing pressures and soon faces biosimilar threat

Bristol-Myers Squibb (BMS) building

BMS shines in Q1, but Abilify generics cast a long shadow

Revenue up 6% but Ablify’s contribution likely to drop due to competition

- PMLiVE

Sanofi wins European approval for Lantus follow-up Toujeo

Long-acting insulin is a key part of the company's growth plans

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links